<p>There's a growing body of research pointing to the therapeutic applications for psychedelics, including MDMA and psilocybin, along with ketamine which was approved for therapeutic use in 2020. The promise of a new frontier in treatment for depression, anxiety and PTSD is an appealing one for researchers and patients desperately looking for solutions in a mental health crisis. But with all the excitement around psychedelics in therapy, where does the research stand, and what risks should patients be aware of? To answer those questions, Just Asking brought out two guests. Leah Mayo is an Assistant Professor in the Department of Psychiatry at the University of Calgary and the Parker Research Chair in Psychedelics. Ron Shore is the Interim Assistant Scientific Director of the Canadian Institute of Military and Veteran Health Research and an Assistant Professor in the Department of Psychiatry, at Queen’s University in Kingston.</p>